Evidence map›Paper›PMID 29172379›Full record

ArticleInternational journal of health policy and management2017

New Health Technologies: A UK Perspective Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".

Nassim Parvizi, Sahar Parvizi

Abstract readComment
In one paragraph

Article in International journal of health policy and management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Why Learning How to Chase Butterflies Matters: A Response to Recent Commentaries.International journal of health policy and management · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nassim ParviziOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Sahar ParviziMoorfields Eye Hospital NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New health technologies require development and evaluation ahead of being incorporated into the patient care pathway. In light of the recent publication by Lehoux et al who discuss the role of entrepreneurs, investors and regulators in providing value to new health technologies, we summarise the processes involved in making new health technologies available for use in the United Kingdom.

Indexed as

Biomedical TechnologyTechnology Assessment, BiomedicalDelivery of Health CareGovernment AgenciesHumansUnited KingdomHealth TechnologyHealth Technology Assessment (HTA)National Institute for Health and Care ExcellenceNational Institute of Health Research (NIHR)

Identifiers

PMID29172379
PMCPMC5726322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.